Development of the multi-tyrosine kinase inhibitor TKI258 for patients with metastatic renal cell carcinoma progressing on an mTOR-inhibitor- preliminary results of a phase I/II trial

被引：0
|
作者：
Gschwend, J. [1 ]
Gruenwald, V. [2 ]
Pande, A. [3 ]
Albrecht, M. [4 ]
Anak, O. [5 ]
Escudier, B. [6 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin, D-8000 Munich, Germany
[2] Hannover Med Sch, Klin Hamatol Hamostaseol & Onkol, D-30623 Hannover, Germany
[3] Novartis Pharma AG, Global Oncol Translat Med, E Hanover, NJ USA
[4] Novartis Pharma GmbH, Klin Entwicklung Onkol, Nurnberg, Germany
[5] Novartis Pharma AG, Oncol Business Unit, Basel, Switzerland
[6] Inst Gustave Roussy, Villejuif, France
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [1] A PHASE I/II STUDY OF TKI258 (DOVITINIB), A FGFR AND VEGFR INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC RENAL CELL CANCER (MRCC): PRELIMINARY PHASE II RESULTS
    Angevin, E.
    Gruenwald, V.
    Lin, C.
    Ravaud, A.
    Lopez, J. A.
    Kruit, W.
    Tykodi, S.
    Gschwend, J.
    Harzstark, A.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 166 - 166
  • [2] TKI258, a Multi-tyrosine Kinase Inhibitor Is Efficacious Against Human Infant/Childhood Lymphoblastic Leukemia In Vitro
    Eucker, Jan
    Zang, Chuanbing
    Zhou, Yongan
    Li, Xinhua
    Habbel, Piet
    Schulz, Carsten-Oliver
    Scholz, Christian
    Liu, Hongyu
    ANTICANCER RESEARCH, 2014, 34 (09) : 4899 - 4907
  • [3] Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
    Escudier, Bernard
    Gruenwald, Viktor
    Ravaud, Alain
    Ou, Yen-Chuan
    Castellano, Daniel
    Lin, Chia-Chi
    Gschwend, Juergen E.
    Harzstark, Andrea
    Beall, Sarah
    Pirotta, Nicoletta
    Squires, Matthew
    Shi, Michael
    Angevin, Eric
    CLINICAL CANCER RESEARCH, 2014, 20 (11) : 3012 - 3022
  • [4] Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
    Angevin, Eric
    Lopez-Martin, Jose A.
    Lin, Chia-Chi
    Gschwend, Juergen E.
    Harzstark, Andrea
    Castellano, Daniel
    Soria, Jean-Charles
    Sen, Paramita
    Chang, Julie
    Shi, Michael
    Kay, Andrea
    Escudier, Bernard
    CLINICAL CANCER RESEARCH, 2013, 19 (05) : 1257 - 1268
  • [5] Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).
    Au, Trang H.
    Bailey, Erin B.
    Patel, Shiven B.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic rental cell cancer: Phase I results.
    Angevin, E.
    Lin, C.
    Pande, A. U.
    Lopez, J. A.
    Gschwend, J.
    Harzstark, A. L.
    Shi, M.
    Anak, O.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)
    Angevin, E.
    Gruenwald, V.
    Ravaud, A.
    Castellano, D. E.
    Lin, C. C.
    Gschwend, J. E.
    Harzstark, A. L.
    Chang, J.
    Wang, Y.
    Shi, M. M.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
    Sarker, Debashis
    Molife, Rhoda
    Evans, T. R. Jeffrey
    Hardie, Maryon
    Marriott, Cheryl
    Butzberger-Zimmerli, Priska
    Morrison, Rosemary
    Fox, Judith A.
    Heise, Carla
    Louie, Sharianne
    Aziz, Natasha
    Garzon, Felix
    Michelson, Glenn
    Judson, Ian R.
    Jadayel, Dalal
    Braendle, Edgar
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2008, 14 (07) : 2075 - 2081
  • [9] Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.
    Motzer, Robert John
    Porta, Camillo
    Bjarnason, Georg A.
    Szcylik, Cezary
    Rha, Sun Young
    Esteban, Emilio
    De Giorgi, Ugo
    MacKenzie, Mary J.
    Mainwaring, Paul N.
    North, Scott
    Sabbatini, Roberto
    Bodrogi, Istvan
    Kabbinavar, Fairooz
    Carteni, Giacomo
    Sternberg, Cora N.
    Vogelzang, Nicholas J.
    Shi, Michael
    Urbanowitz, Gladys
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).
    Esteban, Emilio
    del Muro, Xavier Garcia
    Sepulveda, Juan Manuel
    Maroto, Pablo
    Diaz, Enrique Gallardo
    del Alba, Aranzazu Gonzalez
    Etxaniz, Olatz
    Guix, Marta
    Gonzalez-Larriba, Jose-Luis
    Arija, Jose Angel Arranz
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345